• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.64% Nasdaq Down0.55%

    Actavis plc (ACT)

    306.81 Down 6.27(2.00%) May 29, 4:05PM EDT
    |After Hours : 307.98 Up 1.17 (0.38%) May 29, 7:59PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Actavis plc
    Morris Corporate Center III
    400 Interpace Parkway
    Parsippany, NJ 07054
    United States - Map
    Phone: 862-261-7000
    Website: http://www.actavis.ie

    Index Membership:N/A
    Industry:Drugs - Generic
    Full Time Employees:21,600

    Business Summary 

    Actavis plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic, branded generic, branded, biosimilar, and over-the-counter (OTC) pharmaceutical products. It operates in three segments: North American Brands, North American Generics and International, and Anda Distribution. The North American Brands segment provides patented and off-patent trademarked pharmaceutical products primarily under the Dalvance, Bystolic, Canasa, Carafate, Daliresp, Fetzima, Linzess, Namenda, Namenda XR, Saphris, Teflaro, Viibryd, Actonel, Asacol HD, Atelvia, Delzicol, Doryx, Estrace Cream, Enablex, Lo Loestrin Fe, and Minastrin 24 Fe brands. The North American Generics and International segment develops, manufactures, and sells generic, branded generic, and OTC pharmaceutical products. The Anda Distribution segment distributes generic and brand pharmaceutical products primarily to independent pharmacies, pharmacy chains and buying groups, and physician’s offices. The company also develops and out-licenses generic pharmaceutical products primarily in Europe through its third-party business; and provides products in women's health, gastroenterology, urology, and dermatology areas. The company sells its generic and brand pharmaceutical products primarily to drug wholesalers, retailers, and distributors, including national retail drug and food store chains, hospitals, clinics, mail order retailers, government agencies, and managed healthcare providers. It has a collaboration agreements with Amgen, Inc. to develop and commercialize biosimilar versions of Herceptin, Avastin, Rituxan/Mab Thera, and Erbitux; Ironwood Pharmaceuticals to develop and commercialize Linzessfor the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation; Sanofi-Aventis U.S. LLC; and Trevena for the development of TRV027. Actavis plc was founded in 1983 and is headquartered in Parsippany, New Jersey.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Actavis plc

    Corporate Governance 
    Actavis plc’s ISS Governance QuickScore as of May 1, 2015 is 8. The pillar scores are Audit: 10; Board: 4; Shareholder Rights: 4; Compensation: 8.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. Paul M. Bisaro , 54
    Exec. Chairman
    Mr. Brenton L. Saunders J.D., 45
    Chief Exec. Officer, Pres and Director
    Ms. Maria Teresa Hilado , 50
    Chief Financial Officer and Exec. VP
    Mr. Robert A. Stewart , 47
    Chief Operating Officer and Exec. VP
    Mr. William Meury , 46
    Pres of Branded Pharma
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders